Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis
Authors:
- E. Asin-PrietoEAE. Asin-Prieto
- A. Rodriguez-GasconARA. Rodriguez-Gascon
- I. F. TroconizI. F. Troconiz
- A. SoraluceASA. Soraluce
- J. MaynarJMJ. Maynar
- J. A. Sanchez-IzquierdoJSJ. A. Sanchez-Izquierdo
- A. IslaAIA. Isla
- 1 August 2013
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 69 (1) , 180-189
Abstract
To evaluate the pharmacokinetics of piperacillin/tazobactam in critically ill patients undergoing continuous renal replacement therapy (CRRT) and to assess the success of the therapy against susceptible bacteria. Sixteen patients undergoing CRRT with different degrees of renal function were included in the study. Blood and ultrafiltrate samples were drawn after administration of piperacillin/tazobactam (4/0.5 g) every 4, 6 or 8 h. The data were analysed by a population approach using NONMEM 7.2. The probability of target attainment (PTA) of maintaining free piperacillin levels above the MIC during the entire dosing interval was estimated by simulation of intermittent and continuous infusions. The pharmacokinetics of piperacillin and tazobactam were best described by two-compartment models where the elimination of both drugs was conditioned by renal [dependent on creatinine clearance (CLCR)], non-renal and extracorporeal clearances. A 20 min infusion of piperacillin/tazobactam administered every 6 h provided high PTAs against MICs ≤ 32 mg/L in patients with severe renal failure. In patients with normal or moderate renal function PTAs ≥ 90% were only obtained up to MICs ≤ 8 mg/L with short infusions. However, simulating continuous infusion, higher probabilities of success were obtained against MICs of 32 and 16 mg/L when CLCR was 50 and 100 mL/min, respectively. Population pharmacokinetic models have been developed and validated for piperacillin and tazobactam. Based on the pharmacokinetic/pharmacodynamic analysis, dosing recommendations are given considering the residual renal function of the patient and the MIC for the isolated bacteria.Keywords
This publication has 29 references indexed in Scilit:
- Population Pharmacokinetics of Piperacillin at Two Dose Levels: Influence of Nonlinear Pharmacokinetics on the Pharmacodynamic ProfileAntimicrobial Agents and Chemotherapy, 2012
- Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects ModelsThe AAPS Journal, 2011
- Drug dosing in continuous renal replacement therapy: general rulesCurrent Opinion in Critical Care, 2007
- Elimination of Piperacillin and Tazobactam by Renal Replacement Therapies with AN69 and Polysulfone Hemofilters: Evaluation of the Sieving CoefficientBlood Purification, 2006
- PsN-Toolkit—A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEMComputer Methods and Programs in Biomedicine, 2005
- Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infectionJournal of Antimicrobial Chemotherapy, 2005
- Quantitation and stability of piperacillin and tazobactam in plasma and ultrafiltrate from patients undergoing continuous venovenous hemofiltration by HPLCBiomedical Chromatography, 2005
- Influence of Renal Function on the Pharmacokinetics of Piperacillin/Tazobactam in Intensive Care Unit Patients During Continuous Venovenous HemofiltrationThe Journal of Clinical Pharmacology, 2005
- Models for time‐varying covariates in population pharmacokinetic‐pharmacodynamic analysisBritish Journal of Clinical Pharmacology, 2004
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976